B2PRIME
30.4.2024 14:31:33 CEST | Business Wire | Press release
B2B Prime Services SC Ltd, a multi-asset Prime of Prime liquidity provider, has achieved another significant regulatory milestone by obtaining a security dealer license in Seychelles. This marks the third license for B2Prime, following those in Cyprus and Mauritius. These jurisdictions serve as key hubs with a high concentration of brokers, and B2Prime is dedicated to serving regulated market participants not only in these locations but also throughout Europe. This latest license underscores B2Prime's commitment to providing trusted and compliant services to its global client base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430008885/en/
B2Prime, a globally renowned multi-asset Prime of Prime liquidity provider, has obtained a security dealer license in Seychelles, expanding its global operations and opening doors to its top-tier liquidity services for local brokers, hedge funds, money managers, institutional clients, and liquidity providers. (Photo: Business Wire)
Seychelles, recognised as a crucial hub for brokers, provides B2Prime with a strategic platform to distribute liquidity locally across all regulated companies.
The newly acquired security dealer license enables the B2Prime group to engage in crucial financial activities, such as negotiating and entering agreements for acquiring, disposing of, subscribing for, or underwriting securities. Additionally, it allows to manage securities transactions, handle sales, and manage portfolios of securities on behalf of the clients.
This significant development will greatly enhance the ability to operate efficiently within global markets, backed by a robust legal framework to offer these services under the strict regulatory oversight of the Seychelles Financial Services Authority (SFSA).
Importance of Seychelles License for B2Prime Clients
Seychelles is becoming an attractive location for brokerages, thanks to its strategic placement between Africa, Asia, and the Middle East and its supportive financial climate. With 182 brokers already registered in Seychelles, there is a clear need for a local liquidity partner that can streamline operations and offer advanced financial and technology solutions.
In response to this demand, B2Prime has strategically expanded its presence by acquiring a security dealer license from the Seychelles Financial Services Authority (SFSA), the regulatory body responsible for the licensing and supervision of financial service providers, including security dealers.
This development eliminates the need for local companies to seek out or connect with liquidity providers in distant financial hubs. Instead, they can directly access B2Prime’s extensive Prime of Prime level liquidity.
B2Prime offers over 225 instruments across six asset classes in CFDs, including FOREX, Cryptos, Spot Indices, Precious Metals, Commodities, and NDFs, all through a single margin account. B2Prime clients benefit from deep liquidity pools sourced from Tier-1 providers, which ensure tight spreads and ultra-fast execution. Connectivity options, including OneZero, PXM, Centroid, T4B, FIX API, and cTrader, further facilitate seamless integration and efficiency.
“Establishing our operations in Seychelles opens doors to our Prime of Prime liquidity and enhanced service levels for local brokers, hedge funds, money managers, institutional clients, and liquidity providers. This step forward aligns perfectly with our goal of providing top-tier financial services worldwide and enables us to offer even greater reliability and seize new opportunities in global markets.”
– Eugenia Mykulyak, Founder & Executive Director of B2Prime
Robust Financial Performance and Future Outlook
Following the strategic initiatives, B2Prime has recently disclosed the financial results for its parent company, B2B Prime Services EU, which highlights robust financial growth in the first quarter of 2024. Total assets in Cyprus surged to €28,969,690.98, a 40.32% increase from the previous year. Client assets held for trading also increased by 47.6% to €26,840,460.11.
In the same period, the shareholders' equity rose by 8%, with year-on-year comparisons showing a 68% growth in total assets and a 64% increase in client assets held for trading. Notably, shareholders' equity experienced an impressive 289% surge. Regulatory Capital Adequacy dramatically improved, too, with B2Prime's own funds soaring nearly 600% from €503,000 to €2,728,000, far exceeding regulatory minimums with CET1 and Tier 1 ratios significantly above the required standards.
These figures highlight a strong balance sheet and show B2Prime’s ongoing devotion to growth and reliability. Soon, the company will also disclose the fiscal report for B2Prime Mauritius, which will further validate its position as a credible and reliable service provider to clients worldwide.
Final Remarks
B2Prime has been actively expanding its global footprint since its establishment in Cyprus in 2020 and Mauritius in 2023. The ongoing strategy aims to position B2Prime as a trusted partner in key financial jurisdictions worldwide. The recent acquisition of a security dealer license in Seychelles is a continuation of these efforts to offer Prime of Prime financial services and exclusive tools to local businesses in Seychelles, enhancing their capabilities and potential to succeed in the global marketplace.
The company is thrilled to start operating as a trusted liquidity provider in Seychelles and partner with local businesses!
Reach out today for market-leading liquidity solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430008885/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom